Erasca Inc (ERAS) did well last session?

While Erasca Inc has overperformed by 2.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ERAS fell by -35.48%, with highs and lows ranging from $3.45 to $1.01, whereas the simple moving average fell by -32.03% in the last 200 days.

On March 26, 2025, Raymond James started tracking Erasca Inc (NASDAQ: ERAS) recommending Outperform. A report published by Jefferies on November 18, 2024, Initiated its previous ‘Buy’ rating for ERAS. CapitalOne also rated ERAS shares as ‘Overweight’, setting a target price of $8 on the company’s shares in an initiating report dated March 11, 2024. BofA Securities January 05, 2024d the rating to Neutral on January 05, 2024, and set its price target from $11 to $6. H.C. Wainwright initiated its ‘Buy’ rating for ERAS, as published in its report on October 11, 2023. Mizuho’s report from March 30, 2023 suggests a price prediction of $9 for ERAS shares, giving the stock a ‘Buy’ rating. Goldman also rated the stock as ‘Buy’.

Analysis of Erasca Inc (ERAS)

One of the most important indicators of Erasca Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -45.82% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 12.35, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

For any stock, average volume can also provide valuable insight into volatility, and ERAS is recording 1.77M average volume. On a monthly basis, the volatility of the stock is set at 7.56%, whereas on a weekly basis, it is put at 3.32%, with a loss of -7.89% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.38, showing growth from the present price of $1.40, which can serve as yet another indication of whether ERAS is worth investing in or should be passed over.

How Do You Analyze Erasca Inc Shares?

Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 43.31%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 52.64% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

ERAS shares are owned by institutional investors to the tune of 52.64% at present.

Hot this week

Do investors need to be concerned about Tonix Pharmaceuticals Holding Corp (TNXP)?

While Tonix Pharmaceuticals Holding Corp has overperformed by 1.33%%,...

Investing in Sonim Technologies Inc (SONM) might be an excellent idea, but the stock is currently overvalued/undervalued

While Sonim Technologies Inc has underperformed by -7.09%%, investors...

Can you now get a good deal on N2OFF Inc’s shares?

While N2OFF Inc has underperformed by -0.54%%, investors are...

Abercrombie & Fitch Co (ANF) deserves closer scrutiny

While Abercrombie & Fitch Co has underperformed by -1.61%%,...

Cracker Barrel Old Country Store Inc (CBRL) produces promising results

While Cracker Barrel Old Country Store Inc has overperformed...

Topics

Do investors need to be concerned about Tonix Pharmaceuticals Holding Corp (TNXP)?

While Tonix Pharmaceuticals Holding Corp has overperformed by 1.33%%,...

Can you now get a good deal on N2OFF Inc’s shares?

While N2OFF Inc has underperformed by -0.54%%, investors are...

Abercrombie & Fitch Co (ANF) deserves closer scrutiny

While Abercrombie & Fitch Co has underperformed by -1.61%%,...

Cracker Barrel Old Country Store Inc (CBRL) produces promising results

While Cracker Barrel Old Country Store Inc has overperformed...

Are So-Young International Inc ADR (SY) shares a good deal now?

While So-Young International Inc ADR has overperformed by 41.88%%,...

Spero Therapeutics Inc (SPRO) requires closer examination

While Spero Therapeutics Inc has underperformed by -2.98%%, investors...

Allogene Therapeutics Inc (ALLO) shows promising results

While Allogene Therapeutics Inc has underperformed by -0.81%%, investors...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.